AUTHOR YEAR

R. A. Agarwal, S. D.;Bakris, G.;Filippatos, G.;Pitt, 2022

F. T. Alconchel, P.;Frola, C.;Spiro, M.;Ciria, R.;R 2022
J. O. Alexandre, P.;Fischer, M. O.;Fellahi, J. L.;Roze 2019
E. S. Baskin, M. A.;Gulleroglu, K.;Ozdemir, B. H.;Yi 2023
N. A. M.-B. Bobadilla, L. E.;Ortega-Trejo, J. A.;Per 2019
D. P. Bolignano, S. C.;Navaneethan, S. D.;Strippoli, 2014
R. S. Chadha, T.;Rajakumar, A.;Shingina, A.;Yoon, U 2023
A. G.-T. Covic, P.;Goldsmith, D. J. A. 2006
E. L. De Martin, M. C.;Emamaullee, J.;Lerut, J.;Pot 2022
K. C.-S. Dickstein, A.;Filippatos, G.;McMurray, J. 2008
J. M. C. Elinoff, L. Y.;Dougherty, E. J.;Awad, K. S.; 2018
O. A. D. Gheith, M.;Nagib, A. M.;Adel, M.;Elserwy, 2022
T. N. Hasegawa, H.;Ota, E.;Levack, W. M. M.;Noma 2021
B. K. Hébraud, N.;Borde, J. S.;Bessières, M. H.;Gali 2008
S. A. A. Hunt, W. T.;Chin, M. H.;Feldman, A. M.;Fra 2005
G. E. Kalambokis, M.;Fotopoulos, A.;Al Bokharhii, J. 2005
A. M. S. Khattab, C. H. L.;Hughes, B. A.;Bodalia, J. 2014
T. H. Lahmer, R.;Schmaderer, C.;Chang, J. X.;Stoc 2012
W. C. Liang, C.;Shi, J.;Ren, Z. L.;Hu, F. Q.;van Goor, 2011
M. V.-J. Medeiros, L.;Hernandez, A. M.;Ramon-Garcia 2017
L. E. O.-T. Morales-Buenrostro, J. A.;Pérez-Villalva 2019
C. M. S. Morkane, G.;Mukhtar, A. M.;Reyntjens, Km 2022
L. A. B. Mortensen, C.;Jensen, B.;Stubbe, J.;Carls 2018
L. A. J. Mortensen, B.;Helligso, A. S. L.;Cibulskyte 2022
L. A. J. Mortensen, B.;Helligsoe, A. S. L.;Tougaard, 2024
F. T. J. Nielsen, B. L.;Marcussen, N.;Skott, O.;Bie, P 2008
F. T. J. Nielsen, B. L.;Hansen, P. B. L.;Marcussen, N. 2013
C. M. F. Oliver, J.;Ingram, N.;Rahman, S.;Krzanicki 2021
J. M. D. Pérez-Rojas, S.;Blanco, J. A.;Cruz, C.;De L 2005
N. G. Polanco, E.;Rivera, F.;Castellanos, I.;Baltar 2012
A. R. Rammohan, M.;Kim, D. S.;Soejima, Y.;Kasahara 2022
G. R. S. Roll, M.;Raptis, D. A.;Jalal, A.;Yan, C. T.; 2022
T. M. E. Shaker, J. D.;Davidson, B. R.;Barth, R. N. 2022
S. B. Singhal, K. K.;Jabbour, I. I.;Anand, S. 2012
R. W. N. Thomsen, S. K.;Hasvold, P.;Sanchez, R. G.; 2018
ABSTRACT
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: Despite the
Are short-term complications associated with poor allograft and patient survival after liver transplantation? A s
Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: rationale an Background:
Long-term effect of eplerenone treatment in children with chronic allograft nephropathy BACKGROUND:
Randomized controlled trial of spironolactone effect in kidney transplant recipients of living donors Purpose: Mi
Aldosterone antagonists for preventing the progression of chronic kidney disease Background:
Anesthesia and Critical Care for the Prediction and Prevention for Small-for-size Syndrome: Guidelines from the
Is it time for spironolactone therapy in dialysis patients?
The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008
Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling
Fludrocortisone Among Adult Renal Transplant Recipients With Persistent Hyperkalemia: Single-Center Objectives:
Aldosterone antagonists for people with chronic kidney disease requiring dialysis Background:
Unusual presentation of primary toxoplasmosis infection in a kidney-transplant patient complicated by A a lthough pr
ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult - Summary
Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites
Remission of hypertension and electrolyte abnormalities following renal transplantation in a patient Apparent m
Mineralocorticoid Receptor Antagonism and Aldosterone Synthesis Inhibition Do Not Improve Glomerulosclerosis and
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats
Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney all Background
Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlledMineralocor
Perioperative fluid management and outcomes in adult deceased donor liver transplantation - A systematic revie
Treatment with spironolactone for 1 year does not improve nitric oxide metabolism in renal transplant INTRODUCTIO
THE EFFECT OF SPIRONOLACTONE ON CALCINEURIN INHIBITOR INDUCED NEPHROTOXICITY-THE SPIRENBACKGROUND
Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients: a Randomized Placebo-Contr BACKGROUND:
Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in co
The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-ter Background:
Not All Piggybacks Are Equal: A Retrospective Cohort Analysis of Variation in Anhepatic Transcaval Pressure Gradi
Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic We showed t
Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment
Does modification of portal pressure and flow enhance recovery of the recipient after living donor liver transpla
Which recipient pretransplant factors, such as MELD, renal function, sarcopenia, and recent sepsis influence suita
Which cava anastomotic techniques are optimal regarding immediate and short-term outcomes after liver transpla
Management of refractory ascites Ascites tha
Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes
10.1093/ndt/gfaa294
10.1111/ctr.14704
10.1016/j.ahj.2019.04.023
10.1111/petr.14557
10.1111/ajt.15406
10.1002/14651858.CD007004.pub3
10.1097/tp.0000000000004803
10.1093/ndt/gfk086
10.1111/ctr.14614
10.1093/eurheartj/ehn309
10.1093/cvr/cvx198
10.6002/ECT.MESOT2021.O27
10.1002/14651858.CD013109.pub2
10.1093/ndtplus/sfn159
10.1161/CIRCULATIONAHA.105.167587
10.1093/ndt/gfh871
10.1515/jpem-2013-0235
10.1159/000339649
10.1093/ndt/gfq514
10.2215/CJN.05300516
10.1152/ajprenal.00606.2018
10.1111/ctr.14651
10.1093/ndt/gfy104.SP748
10.1093/ndt/gfac124.003
10.2215/CJN.0000000000000439
10.1093/ndt/gfn204
10.1186/1471-2369-14-42
10.6002/ect.2021.0050
10.1152/ajprenal.00166.2005
10.1093/ndt/gfr285
10.1111/ctr.14657
10.1111/ctr.14656
10.1111/ctr.14681
10.1097/MJT.0b013e3181ff7a8b
10.1093/ndt/gfx312